REFERENCES
3. Wang WD, Guo YY, Yang ZL, Su GL, Sun ZJ. Sniping cancer stem cells with nanomaterials. ACS Nano. 2023;17:23262-98.
4. Duan H, Liu Y, Gao Z, Huang W. Recent advances in drug delivery systems for targeting cancer stem cells. Acta Pharm Sin B. 2021;11:55-70.
5. Knauer N, Meschaninova M, Muhammad S, et al. Effects of dendrimer-microRNA nanoformulations against glioblastoma stem cells. Pharmaceutics. 2023;15:968.
6. Sabit H, Pawlik TM, Radwan F, et al. Precision nanomedicine: navigating the tumor microenvironment for enhanced cancer immunotherapy and targeted drug delivery. Mol Cancer. 2025;24:160.
7. Croker AK, Allan AL. Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44+ human breast cancer cells. Breast Cancer Res Treat. 2012;133:75-87.
8. Han J, Won M, Kim JH, et al. Cancer stem cell-targeted bio-imaging and chemotherapeutic perspective. Chem Soc Rev. 2020;49:7856-78.
9. Mesrati M, Syafruddin SE, Mohtar MA, Syahir A. CD44: a multifunctional mediator of cancer progression. Biomolecules. 2021;11:1850.
10. Królewska-Daszczyńska P, Wendlocha D, Smycz-Kubańska M, Stępień S, Mielczarek-Palacz A. Cancer stem cells markers in ovarian cancer: clinical and therapeutic significance (review). Oncol Lett. 2022;24:465.
11. Behrooz A, Syahir A, Ahmad S. CD133: beyond a cancer stem cell biomarker. J Drug Target. 2019;27:257-69.
12. Cheng JX, Liu BL, Zhang X. How powerful is CD133 as a cancer stem cell marker in brain tumors? Cancer Treat Rev. 2009;35:403-8.
13. Glumac PM, LeBeau AM. The role of CD133 in cancer: a concise review. Clin Transl Med. 2018;7:18.
14. Ni J, Cozzi P, Hao J, et al. Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway. Int J Biochem Cell Biol. 2013;45:2736-48.
15. Ma I, Allan AL. The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Rev Rep. 2011;7:292-306.
16. Singh S, Brocker C, Koppaka V, et al. Aldehyde dehydrogenases in cellular responses to oxidative/electrophilic stress. Free Radic Biol Med. 2013;56:89-101.
17. Chen C, Zhao S, Karnad A, Freeman JW. The biology and role of CD44 in cancer progression: therapeutic implications. J Hematol Oncol. 2018;11:64.
18. Yang Y, Zhu G, Yang L, Yang Y. Targeting CD24 as a novel immunotherapy for solid cancers. Cell Commun Signal. 2023;21:312.
19. Yang L, Shi P, Zhao G, et al. Targeting cancer stem cell pathways for cancer therapy. Signal Transduct Target Ther. 2020;5:8.
20. Krishnamurthy N, Kurzrock R. Targeting the Wnt/beta-catenin pathway in cancer: update on effectors and inhibitors. Cancer Treat Rev. 2018;62:50-60.
21. Cheng J, Tsuda M, Okolotowicz K, et al. Small-molecule probe reveals a kinase cascade that links stress signaling to TCF/LEF and Wnt responsiveness. Cell Chem Biol. 2021;28:625-635.e5.
22. Yuan X, Wu H, Han N, et al. Notch signaling and EMT in non-small cell lung cancer: biological significance and therapeutic application. J Hematol Oncol. 2014;7:87.
23. Alvarez-Trotta A, Guerrant W, Astudillo L, et al. Pharmacological disruption of the notch1 transcriptional complex inhibits tumor growth by selectively targeting cancer stem cells. Cancer Res. 2021;81:3347-57.
24. Zhou HM, Zhang JG, Zhang X, Li Q. Targeting cancer stem cells for reversing therapy resistance: mechanism, signaling, and prospective agents. Signal Transduct Target Ther. 2021;6:62.
25. Chen K, Zhang C, Ling S, Wei R, Wang J, Xu X. The metabolic flexibility of quiescent CSC: implications for chemotherapy resistance. Cell Death Dis. 2021;12:835.
26. Chen CL, Uthaya Kumar DB, Punj V, et al. NANOG Metabolically reprograms tumor-initiating stem-like cells through tumorigenic changes in oxidative phosphorylation and fatty acid metabolism. Cell Metab. 2016;23:206-19.
27. Luo X, Cheng C, Tan Z, et al. Emerging roles of lipid metabolism in cancer metastasis. Mol Cancer. 2017;16:76.
28. Diehn M, Cho RW, Lobo NA, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature. 2009;458:780-3.
29. Huang H, Zhang S, Li Y, et al. Suppression of mitochondrial ROS by prohibitin drives glioblastoma progression and therapeutic resistance. Nat Commun. 2021;12:3720.
30. Wang H, Zhang Z, Ruan S, et al. Regulation of iron metabolism and ferroptosis in cancer stem cells. Front Oncol. 2023;13:1251561.
31. Wang X, Chen Y, Wang X, et al. Stem cell factor SOX2 confers ferroptosis resistance in lung cancer via upregulation of SLC7A11. Cancer Res. 2021;81:5217-29.
32. Tuy K, Rickenbacker L, Hjelmeland AB. Reactive oxygen species produced by altered tumor metabolism impacts cancer stem cell maintenance. Redox Biol. 2021;44:101953.
33. Mohyeldin A, Garzón-Muvdi T, Quiñones-Hinojosa A. Oxygen in stem cell biology: a critical component of the stem cell niche. Cell Stem Cell. 2010;7:150-61.
34. Winkler J, Abisoye-Ogunniyan A, Metcalf KJ, Werb Z. Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat Commun. 2020;11:5120.
35. van Tienderen GS, Rosmark O, Lieshout R, et al. Extracellular matrix drives tumor organoids toward desmoplastic matrix deposition and mesenchymal transition. Acta Biomater. 2023;158:115-31.
36. Wang D, Li Y, Ge H, Ghadban T, Reeh M, Güngör C. The extracellular matrix: a key accomplice of cancer stem cell migration, metastasis formation, and drug resistance in PDAC. Cancers (Basel). 2022;14:3998.
37. Zheng X, Yu C, Xu M. Linking Tumor microenvironment to plasticity of cancer stem cells: mechanisms and application in cancer therapy. Front Oncol. 2021;11:678333.
38. Chen WJ, Ho CC, Chang YL, et al. Cancer-associated fibroblasts regulate the plasticity of lung cancer stemness via paracrine signalling. Nat Commun. 2014;5:3472.
39. Clara JA, Monge C, Yang Y, Takebe N. Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update. Nat Rev Clin Oncol. 2020;17:204-32.
40. Li D, Wang L, Jiang B, Jing Y, Li X. Improving cancer immunotherapy by preventing cancer stem cell and immune cell linking in the tumor microenvironment. Biomed Pharmacother. 2024;170:116043.
41. Zhang Z, Ding C, Sun T, Wang L, Chen C. Tumor therapy strategies based on microenvironment-specific responsive nanomaterials. Adv Healthc Mater. 2023;12:e2300153.
42. Wang X, Li C, Wang Y, et al. Smart drug delivery systems for precise cancer therapy. Acta Pharm Sin B. 2022;12:4098-121.
43. Zhang Z, Deng Q, Xiao C, Li Z, Yang X. Rational design of nanotherapeutics based on the five features principle for potent elimination of cancer stem cells. Acc Chem Res. 2022;55:526-36.
44. Wang Q, Cao H, Hou X, et al. Cancer stem-like cells-oriented surface self-assembly to conquer radioresistance. Adv Mater. 2023;35:e2302916.
45. Liu H, Xu S, Yong T, et al. Hydrophobicity-adaptive polymers trigger fission of tumor-cell-derived microparticles for enhanced anticancer drug delivery. Adv Mater. 2023;35:e2211980.
46. Jia X, Wang E, Wang J. Rational design of nanozymes for engineered cascade catalytic cancer therapy. Chem Rev. 2025;125:2908-52.
47. Gong J, Ding Q, Shi Y, et al. NIR-responsive gold nanomaterials in photothermal antibacterial therapy: from morphological design to multifunctional platforms. Coordin Chem Rev. 2025;526:216348.
48. Younis MR, Wang C, An R, et al. Low power single laser activated synergistic cancer phototherapy using photosensitizer functionalized dual plasmonic photothermal nanoagents. ACS Nano. 2019;13:2544-57.
49. Hu Z, Li J, Feng L, et al. Coassembly of dual-modulated AIE-ESIPT photosensitizers and UCNPs for Enhanced NIR-excited photodynamic therapy. Nano Lett. 2024;24:16426-35.
50. Yu C, Chen D, Zhu D, et al. Dual strategy of C2+ a influx and collagen denaturation to remodel the extracellular matrix and amplify sonopiezoelectric therapy. Adv Mater. 2025;37:e2501642.
51. Zhu Y, Liu T, Deng X, et al. Ultrasound-mediated intra-/extracellular dual intervening effect combined with all-trans retinoic acid for cancer stemness inhibition. Nano Today. 2024;55:102207.
52. Sheng D, Liu T, Qian L, et al. Sonodynamic and sonomechanical effect on cellular stemness and extracellular physicochemical environment to potentiate chemotherapy. J Nanobiotechnology. 2024;22:358.
53. Belova V, Gorin DA, Shchukin DG, Möhwald H. Selective ultrasonic cavitation on patterned hydrophobic surfaces. Angew Chem Int Ed Engl. 2010;49:7129-33.
54. Xu Z, Zeng Y, Kang M, et al. Dual-Enhanced sonodynamic therapy: synergizing cavitation amplification and efficient sonoluminescence-to-ROS conversion for orthotopic breast cancer treatment. Adv Mater. 2026;38:e16803.
55. Bai Y, Jiang K, Deng W, et al. Ultrasound-triggered piezoelectric biomaterials for enhanced cancer sonodynamic immunotherapy. Ultrason Sonochem. 2025;119:107402.
56. An J, Hong H, Won M, et al. Mechanical stimuli-driven cancer therapeutics. Chem Soc Rev. 2023;52:30-46.
57. Fan X, Chen H, Li Y, et al. Actin-targeted magnetic nanomotors mechanically modulate the tumor mechanical microenvironment for cancer treatment. ACS Nano. 2025;19:6454-67.
58. Mai TT, Hamaï A, Hienzsch A, et al. Salinomycin kills cancer stem cells by sequestering iron in lysosomes. Nat Chem. 2017;9:1025-33.
59. Zhao T, Chen Y, Yuan H, et al. One-stone-two-birds carrier-free nano-cocktail enables synergistic eradication of cancer cells/stem cells in breast cancer treatment. Exploration (Beijing). 2026;6:20240259.
60. Cosialls E, El Hage R, Dos Santos L, Gong C, Mehrpour M, Hamaï A. Ferroptosis: cancer stem cells rely on iron until “to die for” it. Cells. 2021;10:2981.
61. Feng Q, Fang W, Guo Y, Hu P, Shi J. Nebulized therapy of early orthotopic lung cancer by iron-based nanoparticles: macrophage-regulated ferroptosis of cancer stem cells. J Am Chem Soc. 2023;145:24153-65.
62. Wu K, Zhang W, Chen H, et al. An iron oxyhydroxide-based nanosystem sensitizes ferroptosis by a “three-pronged” strategy in breast cancer stem cells. Acta Biomater. 2023;160:281-96.
63. Zhu Y, Deng X, Dai Z, et al. A “ferroptosis-amplifier” hydrogel for eliminating refractory cancer stem cells post-lumpectomy. Nano Lett. 2024;24:8179-88.
64. Zhu Y, Deng X, Dai Z, Ning M, Miao R, Chen H. Ultrasound-orchestrated collapse of cancer stem cell niches through synergistic physical barrier disruption and intracellular homeostasis reprogramming. Biomaterials. 2026;331:124138.
65. Bonab M, Salehi S, Aghababaie A, Amini A, Alizadeh H, Behnam B. Mitochondrial hijacking and MicroRNA crosstalk: cancer stem cell-mediated immune evasion and metabolic plasticity in the tumor microenvironment. Cancers (Basel). 2026;18:1611.
66. Pacifico F, Leonardi A, Crescenzi E. Glutamine metabolism in cancer stem cells: a complex liaison in the tumor microenvironment. Int J Mol Sci. 2023;24:2337.
67. Wang Q, Li S, Xu C, et al. Glutaminolysis inhibition boosts photodynamic therapy to eliminate cancer stem cells. Biomaterials. 2024;306:122497.
68. Tsvetkov P, Coy S, Petrova B, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science. 2022;375:1254-61.
69. Xiao C, Wang X, Li S, et al. A cuproptosis-based nanomedicine suppresses triple negative breast cancers by regulating tumor microenvironment and eliminating cancer stem cells. Biomaterials. 2025;313:122763.
70. Lv M, Liu B, Duan Y, et al. Engineered biomimetic nanovesicles synergistically remodel folate-nucleotide and γ-aminobutyric acid metabolism to overcome sunitinib-resistant renal cell carcinoma. ACS Nano. 2024;18:27487-502.
71. Pan Y, Yuan C, Zeng C, et al. Cancer stem cells and niches: challenges in immunotherapy resistance. Mol Cancer. 2025;24:52.
72. Chitty JL, Cox TR. The extracellular matrix in cancer: from understanding to targeting. Trends Cancer. 2025;11:839-49.
73. Safaei S, Sajed R, Shariftabrizi A, et al. Tumor matrix stiffness provides fertile soil for cancer stem cells. Cancer Cell Int. 2023;23:143.
74. Xu F, Huang X, Wang Y, Zhou S. A size-changeable collagenase-modified nanoscavenger for increasing penetration and retention of nanomedicine in deep tumor tissue. Adv Mater. 2020;32:e1906745.
75. Geng M, Du H, Wei X, et al. Engineered platelets-based nano-aircraft system for precise tumor chemo-immunotherapy with graded drug delivery and self-recognized tumor targeting. Sci Bull (Beijing). 2025;70:1462-77.
76. Yang T, Wang Q, Wang L, et al. A unified biochemical-physical regulatory nanoparticle modulates tumor mechanics to augment nanomedicine penetration and antitumor efficacy. J Control Release. 2026;393:114832.
77. Chen J, Xu X, Si W, et al. Ultrasound-triggered peroxynitrite-mediated ECM degradation to enhance sonodynamic cancer therapy. Adv Healthc Mater. 2026;15:e05513.
78. Peng G, Liu Y. Hypoxia-inducible factors in cancer stem cells and inflammation. Trends Pharmacol Sci. 2015;36:374-83.
79. Lam BS, Adams GB. Blocking HIF1α activity eliminates hematological cancer stem cells. Cell Stem Cell. 2011;8:354-6.
80. Wang Y, Wang Y, Sun Y, et al. Ultrathin oleanolic acid/perfluorocarbon-ferrocene nanosheets trigger reactive species storm to reshape tumor microenvironment for enhanced chemodynamic therapy. ACS Nano. 2026;20:7831-47.
81. Ma X, Yao M, Shi J, et al. High intensity focused ultrasound-responsive and ultrastable cerasomal perfluorocarbon nanodroplets for alleviating tumor multidrug resistance and epithelial-mesenchymal transition. ACS Nano. 2020;14:15904-18.
82. Xie Y, Zhang C, Zhao Y, et al. Simultaneous modulation of hypoxia and metabolism in glioblastoma for enhanced radio-immunotherapy. Adv Funct Mater. 2024;34:2312197.
83. Yu LY, Shueng PW, Chiu HC, et al. Glucose transporter 1-mediated transcytosis of glucosamine-labeled liposomal ceramide targets hypoxia niches and cancer stem cells to enhance therapeutic efficacy. ACS Nano. 2023;17:13158-75.
84. Chen Q, Deng B, Luo Q, Song G. Deep tumor‐penetrated nanosystem eliminates cancer stem cell for highly efficient liver cancer therapy. Chem Eng J. 2021;421:127874.
85. Zhao C, Wang W, Huang Z, et al. Small-sized twin-nanoparticles normalize tumor vasculature to enhance tumor accumulation and penetration for potent eradication of cancer stem-like cells. Acta Pharm Sin B. 2025;15:5458-73.
86. Guo D, Ji X, Xie H, et al. Targeted reprogramming of vitamin B3 metabolism as a nanotherapeutic strategy towards chemoresistant cancers. Adv Mater. 2023;35:e2301257.
87. Zhong H, Zhou S, Yin S, Qiu Y, Liu B, Yu H. Tumor microenvironment as niche constructed by cancer stem cells: breaking the ecosystem to combat cancer. J Adv Res. 2025;71:279-96.
88. Liu R, Su L, Gao S, Liu W, Wang H. Cancer-associated fibroblasts functions as multifunctional architects of the tumor stroma and represent emerging therapeutic vulnerabilities. Adv Sci (Weinh). 2026;13:e10043.
89. Biffi G, Tuveson DA. Diversity and biology of cancer-associated fibroblasts. Physiol Rev. 2021;101:147-76.
90. Xue X, Wang X, Pang M, et al. An exosomal strategy for targeting cancer-associated fibroblasts mediated tumors desmoplastic microenvironments. J Nanobiotechnology. 2024;22:196.
91. Bai R, Li Y, Jian L, Yang Y, Zhao L, Wei M. The hypoxia-driven crosstalk between tumor and tumor-associated macrophages: mechanisms and clinical treatment strategies. Mol Cancer. 2022;21:177.
92. Yuan H, Qiu Y, Mei Z, et al. Cancer stem cells and tumor-associated macrophages: Interactions and therapeutic opportunities. Cancer Lett. 2025;624:217737.
93. Yang Z, Luo Y, Yu H, et al. Reshaping the tumor immune microenvironment based on a light-activated nanoplatform for efficient cancer therapy. Adv Mater. 2022;34:e2108908.
94. Jiang M, Li X, Zhang J, et al. Dual Inhibition of endoplasmic reticulum stress and oxidation stress manipulates the polarization of macrophages under hypoxia to sensitize immunotherapy. ACS Nano. 2021;15:14522-34.
95. Pan Y, Yu L, Liu L, et al. Genetically engineered nanomodulators elicit potent immunity against cancer stem cells by checkpoint blockade and hypoxia relief. Bioact Mater. 2024;38:31-44.
96. Zhang T, Wei Y, Liu Z, et al. In situ engineered “cascade-amplified” drug-loaded vesicles for enhanced cancer stem cell therapy. J Extracell Vesicles. 2026;15:e70292.
97. Gao S, Liu M, Zhang Y, et al. A precision intelligent nanomissile for inhibiting tumor metastasis, boosting energy deprivation and immunotherapy. Biomaterials. 2025;315:122953.
98. Wu Y, Diao P, Peng Y, et al. A hybrid manganese nanoparticle simultaneously eliminates cancer stem cells and activates STING pathway to potentiate cancer immunotherapy. ACS Nano. 2025;19:12237-52.
99. Shen S, Xu X, Lin S, et al. A nanotherapeutic strategy to overcome chemotherapeutic resistance of cancer stem-like cells. Nat Nanotechnol. 2021;16:104-13.
100. Pan Y, Ma X, Liu C, et al. Retinoic acid-loaded dendritic polyglycerol-conjugated gold nanostars for targeted photothermal therapy in breast cancer stem cells. ACS Nano. 2021;15:15069-84.
101. Li Z, Yang J, Ren B, et al. Double-layered hollow mesoporous cuprous oxide nanoparticles for double drug sequential therapy of tumors. Adv Mater. 2024;36:e2313212.
102. Sarkar R, Biswas S, Ghosh R, et al. Exosome-sheathed porous silica nanoparticle-mediated co-delivery of 3,3'-diindolylmethane and doxorubicin attenuates cancer stem cell-driven EMT in triple negative breast cancer. J Nanobiotechnology. 2024;22:285.
103. Liu J, Smith S, Wang C. Reversing the epithelial-mesenchymal transition in metastatic cancer cells using CD146-targeted black phosphorus nanosheets and a mild photothermal treatment. ACS Nano. 2022;16:3208-20.
104. Liu J, Smith S, Wang C. Photothermal attenuation of cancer cell stemness, chemoresistance, and migration using CD44-targeted MoS2 nanosheets. Nano Lett. 2023;23:1989-99.
105. Yun Y, Kim S, Lee SN, Cho HY, Choi JW. Nanomaterial-based detection of circulating tumor cells and circulating cancer stem cells for cancer immunotherapy. Nano Converg. 2024;11:56.
106. Li B, Tian J, Zhang F, et al. Self-assembled aldehyde dehydrogenase-activatable nano-prodrug for cancer stem cell-enriched tumor detection and treatment. Nat Commun. 2024;15:9417.
107. Zheng F, Lan Z, Chen H, Ma M. Engineering bone-mimetic microspheres to recapitulate the tumor microenvironment for in vitro osteosarcoma modeling. Biomedicines. 2026;14:868.
108. Ravi K, Manoharan TJM, Wang KC, Pockaj B, Nikkhah M. Engineered 3D ex vivo models to recapitulate the complex stromal and immune interactions within the tumor microenvironment. Biomaterials. 2024;305:122428.
109. Hu W, Bei HP, Jiang H, et al. DLM-GelMA/tumor slice sandwich structured tumor on a chip for drug efficacy testing. Lab Chip. 2024;24:3718-27.
